Prognostic factors for the Coronavirus disease 2019 (COVID1–9) are not well established. This study aimed to summarize the available data on the association between the severity of COVID-19 and common hematological, inflammatory and biochemical parameters. EMBASE, MEDLINE, Web of sciences were searched to identify all published studies providing relevant data. Random-effects meta-analysis was used to pool effect sizes. The bibliographic search yielded 287 citations, 31 of which were finally retained. Meta-analysis of standardized mean difference (SMD) between severe and non-severe COVID-19 cases showed that CK-MB (SMD = 0.68,95%CI: 0.48;0.87; P-value:< 0.001), troponin I (SMD = 0.71, 95%CI:0.42;1.00; P-value:< 0.001), D-dimer (SMD = 0.54,95%CI:0.31;0.77; P-value:< 0.001), prothrombin time (SMD = 0.48, 95%CI:0.23;0.73; P-value: < 0.001), procalcitonin (SMD = 0.72, 95%CI: 0.34;1,11; P-value:< 0.001), interleukin-6 (SMD = 0.93, 95%CI: 0.25;1.61;P-value: 0.007),C-reactive protein (CRP) (SMD = 1.34, 95%CI:0.83;1.86; P-value:< 0.001), ALAT (SMD = 0.53, 95%CI: 0.34;0,71; P-value:< 0.001), ASAT (SMD = 0.96, 95%CI: 0.58;1.34; P-value: < 0.001), LDH (SMD = 1.36, 95%CI: 0.75;1.98; P-value:< 0.001), CK (SMD = 0.48, 95%CI: 0.10;0.87; P-value:0.01), total bilirubin (SMD = 0.32, 95%CI: 0.18;0.47;P-value: < 0.001), γ-GT (SMD = 1.03, 95%CI: 0.83;1.22; P-value: < 0.001), myoglobin (SMD = 1.14, 95%CI: 0.81;1.47; P-value:< 0.001), blood urea nitrogen (SMD = 0.32, 95%CI: 0.18;0.47;P-value:< 0.001) and Creatininemia (SMD = 0.18, 95%CI: 0.01;0.35; P-value:0.04) were significantly more elevated in severe cases, in opposition to lymphocyte count (SMD = -0.57, 95%CI:-0.71; − 0.42; P-value: < 0.001) and proportion of lymphocytes (SMD = -0.81, 95%CI: − 1.12; − 0.49; P-value:< 0.001) which were found to be significantly lower in severe patients with other biomarker such as thrombocytes (SMD = -0.26, 95%CI: − 0.48; − 0.04; P-value:0.02), eosinophils (SMD = − 0.28, 95%CI:-0.50; − 0.06; P-value:0.01), haemoglobin (SMD = -0.20, 95%CI: − 0.37,-0.03; P-value:0.02), albuminemia (SMD-1.67,95%CI -2.40; − 0.94; P-value:< 0.001), which were also lower. Furthermore, severe COVID-19 cases had a higher risk to have lymphopenia (RR =1.66, 95%CI: 1.26;2.20; P-value:0.002), thrombocytopenia (RR = 1.86, 95%CI: 1.59;2.17; P-value: < 0.001), elevated procalcitonin level (RR = 2.94, 95%CI: 2.09–4.15; P-value:< 0.001), CRP (RR =1.41,95%CI: 1.17–1.70; P-value:0.003), ASAT(RR =2.27, 95%CI: 1.76;2.94; P-value:< 0.001), CK(RR = 2.61, 95%CI: 1.35;5.05; P-value: 0.01), Creatininemia (RR = 3.66, 95%CI: 1.53;8.81; P-value: 0.02) and LDH blood level (RR = 2.03, 95%CI: 1.42;290; P-value: 0.003). Some inflammatory (procalcitonin, CRP), haematologic (lymphocyte, Thrombocytes), and biochemical (CK-MB, Troponin I, D-dimer, ASAT, ALAT, LDH, γ-GT) biomarkers are significantly associated with severe COVID-19. These biomarkers might help in prognostic risk stratification of patients with COVID-19.

中文翻译：

---

与 2019 年冠状病毒病 (COVID-19) 严重程度相关的潜在生物标志物的荟萃分析。

2019 年冠状病毒病 (COVID1-9) 的预后因素尚未明确。本研究旨在总结有关 COVID-19 严重程度与常见血液学、炎症和生化参数之间关系的现有数据。对 EMBASE、MEDLINE、Web of sciences 进行搜索，以确定所有已发表的提供相关数据的研究。使用随机效应荟萃分析来汇总效应大小。书目检索共获得 287 条引用，其中 31 条最终保留。重症和非重症COVID-19病例标准化平均差（SMD）的荟萃分析显示，CK-MB（SMD=0.68，95%CI：0.48；0.87；P值：<0.001）、肌钙蛋白I（SMD） = 0.71，95%CI：0.42；1.00；P 值：< 0.001），D-二聚体（SMD = 0.54，95%CI：0.31；0.77；P 值：< 0.001），凝血酶原时间（SMD = 0.48， 95%CI：0.23；0.73；P 值：< 0.001），降钙素原（SMD = 0.72，95%CI：0.34；1,11；P 值：< 0.001），白介素-6（SMD = 0.93，95%） CI: 0.25;1.61;P 值: 0.007),C 反应蛋白 (CRP) (SMD = 1.34, 95%CI:0.83;1.86;P 值:< 0.001), ALAT (SMD = 0.53, 95%CI) ：0.34；0,71；P 值：< 0.001），ASAT（SMD = 0.96，95%CI：0.58；1.34；P 值：< 0.001），LDH（SMD = 1.36，95%CI：0.75；1.98） ；P 值：< 0.001）、CK（SMD = 0.48，95%CI：0.10；0.87；P 值：0.01）、总胆红素（SMD = 0.32，95%CI：0.18；0.47；P 值：< 0.001)、γ-GT (SMD = 1.03, 95%CI: 0.83;1.22; P 值: < 0.001)、肌红蛋白 (SMD = 1.14, 95%CI: 0.81;1.47; P 值:< 0.001)、血液尿素氮（SMD = 0.32，95%CI：0.18；0.47；P 值：< 0.001）和肌酐血症（SMD = 0.18，95%CI：0.01；0.35；与淋巴细胞计数（SMD = -0.57，95%CI：-0.71；− 0.42；P 值：< 0.001）和淋巴细胞比例（SMD = - 0.81，95%CI：− 1.12；− 0.49；P 值：< 0.001），发现在具有血小板等其他生物标志物的重症患者中显着较低（SMD = -0.26，95% CI：− 0.48；− 0.04） ；P 值：0.02）、嗜酸性粒细胞（SMD = − 0.28，95%CI：-0.50；− 0.06；P 值：0.01）、血红蛋白（SMD = -0.20，95%CI：− 0.37，-0.03；P -值：0.02）、白蛋白血症（SMD-1.67，95%CI -2.40；− 0.94；P 值：< 0.001），也较低。此外，重症COVID-19病例出现淋巴细胞减少症（RR = 1.66，95% CI：1.26；2.20；P值：0.002）、血小板减少症（RR = 1.86，95% CI：1.59；2.17；P-值：< 0.001)、降钙素原水平升高（RR = 2.94，95%CI：2.09–4.15；P 值：< 0.001）、CRP（RR =1.41，95%CI：1.17–1.70；P 值：0.003） , ASAT(RR = 2.27, 95% CI: 1.76;2.94; P 值:< 0.001), CK(RR = 2.61, 95% CI: 1.35;5.05; P 值: 0.01), 肌酐血症 (RR = 3.66, 95%CI：1.53；8.81；P 值：0.02）和 LDH 血液水平（RR = 2.03，95%CI：1.42；290；P 值：0.003）。一些炎症（降钙素原、CRP）、血液学（淋巴细胞、血小板）和生化（CK-MB、肌钙蛋白 I、D-二聚体、ASAT、ALAT、LDH、γ-GT）生物标志物与重症 COVID-19 显着相关。